|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | ||||||||||||||||||||
| Federal funds sold | ||||||||||||||||||||
| Interest-earning deposits in other financial institutions and other short term investments | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Securities available for sale, at fair value (cost: 2026—$254,538; 2025—$246,579) | ||||||||||||||||||||
| Loans held for sale, at fair value | ||||||||||||||||||||
| Loans receivable | ||||||||||||||||||||
| Less: Allowance for credit losses ("ACL") - loans | ||||||||||||||||||||
| Loans receivable, net | ||||||||||||||||||||
| Office properties and equipment, net | ||||||||||||||||||||
| Federal Home Loan Bank stock, at cost | ||||||||||||||||||||
| Cash surrender value of life insurance | ||||||||||||||||||||
| Real estate owned, net | ||||||||||||||||||||
| Prepaid expenses and other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities: | ||||||||||||||||||||
| Demand deposits | ||||||||||||||||||||
| Money market and savings deposits | ||||||||||||||||||||
| Time deposits | ||||||||||||||||||||
| Total deposits | ||||||||||||||||||||
| Borrowings | ||||||||||||||||||||
| Advance payments by borrowers for taxes | ||||||||||||||||||||
| Other liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Shareholders’ equity: | ||||||||||||||||||||
| Preferred stock (par value $.01 per share) authorized - 50,000,000 shares at June 30, 2026 and at December 31, 2025, no shares issued | ||||||||||||||||||||
| Common stock (par value $.01 per share) authorized - 100,000,000 shares at June 30, 2026 and at December 31, 2025, issued and outstanding - 17,975,028 at June 30, 2026 and 18,359,717 at December 31, 2025 | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Unearned ESOP shares | ||||||||||||||||||||
| Accumulated other comprehensive loss, net of taxes | ||||||||||||||||||||
| Total shareholders’ equity | ||||||||||||||||||||
| Total liabilities and shareholders’ equity | ||||||||||||||||||||
Loading...
